logo

For the Inventor, By the Inventor

Boston, MA, United States of America

Sarah Bethune

This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Imbria Pharmaceuticals, Inc.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sarah Bethune. Retrieved from https://idiyas.com/inventor/sarah-bethune

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 75.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal4 out of 23 
 
Imbria Pharmaceuticals, Inc.
 patents

Years Active: 2022-2026

Loading Chart...
4 patents (USPTO):Explore Patents
1. 12649720 - Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate (2026-06-09),
2. 12065410 - Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate (2024-08-20),
3. 11746090 - Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate (2023-09-05),
4. 11530184 - Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate (2022-12-20),

Title: The Innovative Journey of Inventor Sarah Bethune

Introduction: Sarah Bethune, based in Boston, MA, is an accomplished inventor with a remarkable portfolio that includes three patents. Her innovative contributions primarily focus on polymorphs of pharmaceutical compounds, showcasing her dedication to advancing drug formulations and treatments.

Latest Patents: Among Sarah's latest inventions is the patent for crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate. This invention not only provides unique polymorphs of the compound but also includes pharmaceutical compositions and methods for treating various conditions by utilizing these polymorphs. This significant advancement has the potential to enhance therapeutic efficacy and improve patient outcomes.

Career Highlights: Sarah is currently affiliated with Imbria Pharmaceuticals, Inc., where she applies her expertise in pharmacology and innovative research. Over the years, she has made significant strides in the pharmaceutical field, contributing to the development of new drug formulations that address critical health issues.

Collaborations: Throughout her career, Sarah has collaborated with notable colleagues, including Neil Buckley and Dan Belmont. Their teamwork has fostered a dynamic and innovative environment, leading to groundbreaking research and applications in the realm of pharmaceuticals.

Conclusion: In summary, Sarah Bethune stands out as a pioneering inventor whose work continues to shape the future of pharmaceutical innovations. With her impressive track record and commitment to improving health solutions, she remains an important figure in the world of drug development and therapeutics.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…